Intervention Maps · Chronic low back pain · Medicines

Medicines for low back pain

This page is about oral medicines used for low back pain: NSAIDs, opioids, antidepressants used for pain, gabapentinoids in sciatica conversations, paracetamol, and muscle relaxants. It is not a dosing guide, and it is not a claim that pills rebuild a disc.

Bottom line

Medicines stay on the map for chronic low back pain, but average pain benefits are generally small. No class shows a large placebo-controlled effect. No included class has high- or moderate-certainty evidence of a large or medium placebo-controlled pain effect. Small signals and opioid harms both count. SNRIs probably give a small short-term pain change with more side effects; TCAs probably do not reduce pain. Major guidelines still disagree about some antidepressants. None of this changes the disease itself.

What it is

Medicines used to reduce pain or related symptoms. Different classes have different benefit and harm profiles. In the best current overview, average benefits across classes stay small.

What taking part usually involves

A prescription or over-the-counter course, time-limited trials, and monitoring for side effects. Some medicines are short-horizon tools. Others raise dependence, sedation, or interaction questions.

What this is commonly confused with

“Pills don’t work.” “If NICE says do not offer antidepressants, the trial evidence vanished.” “An antidepressant update automatically settles every guideline.”

What the evidence shows

A Cochrane overview finds no included medicine class with high- or moderate-certainty evidence of a large or medium placebo-controlled pain effect.

Chronic NSAID and opioid signals are small. Opioids add harms.

A later antidepressant review finds SNRIs probably give a small short-term pain reduction, with trivial disability change and more adverse events. TCAs probably do not reduce pain intensity.

NICE still says do not offer antidepressants for low back pain and do not offer gabapentinoids for sciatica. VA/DoD is more open on duloxetine. That disagreement stays live. An updated trial synthesis does not automatically rewrite every guideline sentence.

None of this is disease-modifying.

Who was studied, expectations, and limits

Population and context studied: people with low back pain considering oral medicines, including chronic presentations in the major reviews.

That is the research and guideline conversation, not a personal prescribing decision.

Realistic expectation: average benefits are small for many classes, and harms differ substantially by medicine. Limits: not disc repair; not a substitute for care matched to sciatica or stenosis when that is the real problem.

Evidence consulted Open sources

Key sources used to prepare this answer. This is not a citation for every sentence.

← Back to Chronic low back pain · find this again later from “What are you trying to figure out?”